相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
David Miles et al.
EUROPEAN JOURNAL OF CANCER (2017)
First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
Didier Meulendijks et al.
CLINICAL CANCER RESEARCH (2016)
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going
Francesco Schettini et al.
CANCER TREATMENT REVIEWS (2016)
Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies
Conleth G. Murphy et al.
ENDOCRINE-RELATED CANCER (2016)
Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies
Laurence Lousberg et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody
Georgina Meneses-Lorente et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
Sara A. Hurvitz et al.
LANCET ONCOLOGY (2015)
Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model
Michael D. Curley et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience
Zsuzsanna Varga et al.
PLOS ONE (2015)
Predictive markers in breast cancer: An update on ER and HER2 testing and reporting
Benjamin C. Calhoun et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2015)
Quantitative measurement of HER2 expression in breast cancers: comparison with real world routine HER2 testing in a multi-center Collaborative Biomarker Study and correlation with overall survival
Denise A. Yardley et al.
BREAST CANCER RESEARCH (2015)
Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer
Hee Jin Lee et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications
F. Montemurro et al.
ANNALS OF ONCOLOGY (2013)
Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling
Susan Thrane et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation
Christian Mirschberger et al.
CANCER RESEARCH (2013)
Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance
Rocio Garcia-Becerra et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER
Debu Tripathy et al.
ONCOLOGIST (2013)
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial
J. Huober et al.
BREAST (2012)
New driver mutations in non-small-cell lung cancer
William Pao et al.
LANCET ONCOLOGY (2011)
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation
Yen-Chao Wang et al.
BREAST CANCER RESEARCH (2011)
CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer
Jose Baselga et al.
CLINICAL BREAST CANCER (2010)
Trastuzumab Reverses Letrozole Resistance and Amplifies the Sensitivity of Breast Cancer Cells to Estrogen
Gauri Sabnis et al.
CANCER RESEARCH (2009)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The ERBB3 receptor in cancer and cancer gene therapy
G. Sithanandam et al.
CANCER GENE THERAPY (2008)
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance
Grazia Arpino et al.
ENDOCRINE REVIEWS (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Unraveling the mechanisms of endocrine resistance in breast cancer: New therapeutic opportunities
Suleiman Massarweh et al.
CLINICAL CANCER RESEARCH (2007)
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
M De Laurentiis et al.
CLINICAL CANCER RESEARCH (2005)
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study
G Arpino et al.
CLINICAL CANCER RESEARCH (2004)
Aromatase inhibitors for breast cancer: Lessons from the laboratory
SRD Johnston et al.
NATURE REVIEWS CANCER (2003)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
分享论文
